Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115999 · ClinicalTrials.gov registry record · Phase 3
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
A Phase 3 study of Arterial Occlusive Diseases, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00115999 is a Phase 3 study of Arterial Occlusive Diseases that has completed, run by ARCA Biopharma. The registered enrollment target is 300 participants, roughly in line with the 283-participant average among 4 other Arterial Occlusive Diseases trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00115999, a Phase 3 study of Arterial Occlusive Diseases, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
Conditions Studied
Interventions
- DRUG alfimeprase
Study Locations (1)
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115999
The ClinicalTrials.gov registry entry for NCT00115999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 283-participant average among 4 other Arterial Occlusive Diseases trials with a reported enrollment target. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arterial Occlusive Diseases appearing as the primary indexed condition, and to 1 intervention - of which alfimeprase is the first listed.
NCT00115999 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00115999 about?
NCT00115999 is a clinical study titled "Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries". The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
What is the current status of trial NCT00115999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-04. Estimated completion is 2007-02.
What conditions does trial NCT00115999 study?
This clinical trial studies the following conditions: Arterial Occlusive Diseases.
What interventions are being tested in trial NCT00115999?
The interventions under investigation include: alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00115999?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115999 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arterial Occlusive Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
-
Distributed Registry
COMPLETED
-
The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD
COMPLETED · NA
-
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.